Prostate Cancer Screening Takes a Major Turn as New Guidelines Recommend Regular Testing for Millions of Men
American Cancer Society Introduces Major Changes
Prostate cancer screening is entering a new chapter after the American Cancer Society (ACS) introduced major changes to its screening guidelines on November 12, 2026. The updated recommendations now directly encourage regular prostate-specific antigen (PSA) testing for men at average and higher risk, reversing the organization’s previous approach, which placed greater emphasis on individual discussions with doctors before testing.
The change follows growing evidence that regular screening can help detect prostate cancer earlier, reduce advanced-stage diagnoses, and lower the risk of death. Health experts believe improvements in follow-up testing and treatment decisions have also made screening safer than it was in the past.
Who Should Get Screened and At What Age?
Under the new recommendations, men at average risk should receive a PSA blood test every two years between the ages of 50 and 69.
Men considered at higher risk should begin testing earlier. The guidelines recommend annual screening from age 45 through 69 for Black men and men with a strong family history of prostate cancer.
For men with one close family member diagnosed at age 65 or older, the recommended screening interval is every two years, beginning at age 45.
The recommendations also address men between 70 and 74. Screening decisions for this age group should be based on overall health, previous PSA results, life expectancy, and personal preferences. Routine screening is not recommended for men aged 75 and older.
Why Experts Are Changing Their Position
The previous ACS guideline, published in 2010, did not directly recommend routine screening for all eligible men. Instead, it encouraged patients and doctors to discuss the possible benefits and disadvantages before deciding whether to take a PSA test.
At that time, research offered mixed results about whether screening consistently reduced prostate cancer deaths. There were also concerns that testing could identify slow-growing cancers that might never threaten a man’s life.
Since then, longer-term research has provided stronger evidence that PSA-based screening can reduce prostate cancer mortality. Medical teams have also developed better ways to investigate abnormal results without immediately sending every patient for an invasive procedure.
These developments helped convince the ACS that the benefits of regular screening now outweigh its potential harms for certain age and risk groups.
PSA Blood Tests Remain the Main Screening Method
A PSA test measures the amount of prostate-specific antigen in the blood. Higher levels can sometimes indicate prostate cancer, although an elevated result does not automatically mean someone has the disease.
The updated guidelines recommend repeating an abnormal PSA result before moving toward further investigation. This can help identify temporary increases and prevent unnecessary procedures.
For men with repeatedly elevated PSA levels, doctors may recommend magnetic resonance imaging (MRI) or validated biomarker tests to determine whether a biopsy is necessary.
The organization also advises against using a digital rectal examination as the primary screening method.
New Approach Aims to Reduce Unnecessary Treatment
One of the biggest concerns surrounding prostate cancer screening has been overtreatment. Some prostate cancers grow slowly and may never cause serious health problems during a person’s lifetime.
The new guidance encourages doctors to use active surveillance as the initial approach for men diagnosed with low-risk prostate cancer. This involves monitoring the disease through regular tests rather than immediately starting surgery or radiation treatment.
The ACS also advises against screening men with a life expectancy of less than 10 years. These precautions are designed to help patients receive appropriate care while avoiding unnecessary medical complications.
What Men Should Know About the New Guidelines
The updated recommendations could change how doctors discuss prostate cancer prevention and early detection with their patients.
Men approaching 50 should consider discussing PSA testing with their healthcare providers. Those with a higher risk may need to start the conversation earlier, particularly if prostate cancer runs in their family.
The new guidance applies to the American Cancer Society’s recommendations in the United States. It does not mean every man needs the same testing schedule, and individual medical advice remains important.
Frequently Asked Questions
1. At what age should men start prostate cancer screening?
Men at average risk should begin PSA screening at age 50. Black men and men with a strong family history should generally begin at age 45.
2. How often should men get a PSA test?
Average-risk men aged 50–69 should get tested every two years. Higher-risk men, including Black men and those with a strong family history, should generally receive annual testing.
3. Does a high PSA level always mean prostate cancer?
No. An elevated PSA level does not automatically indicate cancer. Doctors may repeat the test and recommend MRI, biomarker testing, or a biopsy when further investigation is needed.
